KRAS and cholangiocarcinoma: Finally, the data obtained in CCA cell lines unraveled an anti-growth effect by MEK inhibitors even in K-Ras wild-type cells, thus suggesting the usefulness of these drugs in iCCA patients not carrying K-Ras mutation as well.